<PAGE>
As filed with the Securities and Exchange Commission on January 10, 2001
Registration No. 333-51440
===============================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
POST EFFECTIVE AMENDMENT NO. 1
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
NEXELL THERAPEUTICS INC.
(Exact name of Registrant as specified in its charter)
Delaware 06-1192468
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
9 Parker
Irvine, California 92618
(949) 470-9011
(Address, including zip code, and telephone number, including area code, of
Registrant's principal executive offices)
William A. Albright, Jr.
President and Chief Operating Officer
9 Parker
Irvine, California 92618
(949) 470-6485
(Name, address, including zip code, and telephone number, including area code,
of agent for service)
Copies to:
Alan C. Mendelson, Esq.
LATHAM & WATKINS
135 Commonwealth Drive
Menlo Park, California 94025
(650) 328-4600
Approximate date of commencement of proposed sale to the public:
As soon as practicable after this Registration Statement becomes effective.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [_]
If any of the securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, as amended (the "Securities Act"), check the following box. [X]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. [_]
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [_]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [_]
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
Title Of Securities To Be Registered Proposed Maximum Aggregate Offering Price Amount Of Registration Fee (1)
<S> <C> <C>
---------------------------------------------------------------------------------------------------------------------
Common Stock $25,000,000 $6,600 (2)
---------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) Estimated solely for the purpose of computing the amount of the registration
fee in accordance with Rule 457(o) under the Securities Act of 1933.
(2) Filing fee previously paid.
The Registrant hereby amends this Registration Statement on such date as may
be necessary to delay its effective date until the Registrant shall file a
further amendment that specifically states that this Registration Statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
===============================================================================
<PAGE>
PROSPECTUS
NEXELL THERAPEUTICS INC.
9 Parker
Irvine, California 92618
(949) 470-9011
$25,000,000 Aggregate Amount of Common Stock
--------------------
This prospectus will allow us to issue common stock over time. This means:
. we will provide a prospectus supplement each time we issue common stock;
. the prospectus supplement will inform you about the specific terms of
that offering and may also add, update or change information contained
in this document; and
. you should read this document and any prospectus supplement carefully
before you invest.
Nexell Therapeutics Inc. common stock is traded on the Nasdaq National
Market under the symbol "NEXL." On January 5, 2001, the closing sale price of
Nexell common stock on the Nasdaq National Market was $3.00 per share.
This investment involves a high degree of risk. You should purchase
shares only if you can afford a complete loss. See "Risk Factors" beginning on
page 3.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus. Any representation to the
contrary is a criminal offense.
The date of this prospectus is January 10, 2001
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
Prospectus Summary..................................................... 1
The Company............................................................ 1
The Offering........................................................... 2
Risk Factors........................................................... 3
Forward-Looking Statements............................................. 12
Use of Proceeds........................................................ 14
Plan of Distribution................................................... 15
Where You Can Find More Information.................................... 16
Legal Matters.......................................................... 17
Experts................................................................ 17
</TABLE>
i
<PAGE>
Prospectus Summary
The following summary is qualified in its entirety by reference to the more
detailed information and consolidated financial statements appearing elsewhere
or incorporated by reference in this prospectus.
The Company
Nexell Therapeutics Inc. (formerly VIMRX Pharmaceuticals Inc.) is a
biotechnology company that focuses on innovative technologies to improve human
health. Nexell's principal subsidiary, Nexell of California, Inc. is developing
products utilizing cell separation technology in cell therapy for cancer and
other life-threatening diseases. We currently sell cell therapy products in
Europe, the United States and Canada.
1
<PAGE>
The Offering
Common stock offered in this
prospectus................................... ________ shares
Common stock outstanding after
the offering................................. ________ shares (l)
Use of proceeds.............................. See "Use of Proceeds."
Nasdaq National Market symbol................ NEXL
__________________
(1) Based on shares outstanding as of September 30, 2000.
Does not include:
. 2,305,247 shares of common stock issuable upon exercise of outstanding
options as of September 30, 2000;
. 3,911,130 shares of common stock issuable upon exercise of outstanding
warrants as of September 30, 2000; and
. 12,499,817 shares of common stock issuable upon conversion of
outstanding convertible preferred stock as of September 30, 2000.
2
<PAGE>
Risk Factors
An investment in the securities offered by this prospectus is very risky.
You should carefully consider the following risk factors in addition to the
information in the remainder of this prospectus before deciding to purchase the
stock.
These risks and uncertainties are not the only ones we face. Others that
we do not know about now, or that we do not now think are important, may impair
our business or the trading price of our securities.
Investors should consider the following factors:
We have a history of operating losses and may not be profitable.
Since commencing our operations in January 1987, through September 30,
2000, we have incurred an accumulated deficit of approximately $192,287,000.
These losses have resulted principally from costs incurred in research and
development of the Isolex(R) system and our cell culture technologies, general
and administrative expenses, and the prosecution of patent applications. We had
no significant operating revenues until 1998. Revenues since 1998 have been
principally derived from sales of Isolex(R) devices and related disposables. We
expect to incur substantial additional losses over the next several years,
whether or not we continue to generate revenues, as we continue to develop our
products. We expect that these additional losses will result primarily from our
research and development programs, including preclinical and clinical trials,
and the establishment of marketing and distribution capabilities necessary to
support commercialization efforts for our products. We cannot predict with any
certainty the amount of future losses. Our ability to continue to generate
revenue and operating income in the future will depend on many factors,
including:
. establishing manufacturing, sales and marketing capabilities for our
products internally and through collaborative arrangements;
. cost and timing of regulatory approvals and commercial sales of our
products;
. level of competing technologies and market developments;
. protection of our patent and other intellectual rights;
. continued scientific progress in our research and development programs;
and
. Timing and investment in new technologies.
We expect to continue to incur net operating losses for the foreseeable future
and we can give no assurance that we will ever be profitable.
Failure to obtain and maintain required regulatory approvals would restrict our
ability to sell our products and earn revenues.
Our development activities of our technologies are intended to lead to new
drugs and medical devices that must obtain the approval of the United States
Food and Drug Administration before sales
3
<PAGE>
may be made in the United States, and the approval of foreign regulators before
sales may be made in foreign jurisdictions. The process of obtaining and
maintaining regulatory approvals for new drugs and medical devices is lengthy,
expensive and uncertain. The manufacturing, distribution, advertising and
marketing of these products are also subject to extensive regulation. If we
cannot demonstrate the safety, reliability and efficacy of our product
candidates, we will not obtain required regulatory approvals and our revenues
will suffer. Noncompliance with applicable requirements can result in, among
other things, fines, injunctions, civil penalties, recall or seizure of
products, total or partial suspension of production, failure of the FDA to grant
premarket clearance or premarket approval for devices, withdrawal of marketing
clearances or approvals, and criminal prosecution. The FDA also has the
authority to request recall, repair, replacement or refund of the cost of any
device manufactured or distributed by us.
Even after regulatory approval of a product is granted, that approval may
be subject to limitations on the indicated uses for which it may be marketed.
In addition, the FDA, other regulatory agencies and governments in other
countries continue to review and inspect marketed products, manufacturers and
manufacturing facilities after regulatory approval is granted. Later discovery
of previously unknown problems with a product, manufacturer or facility may
result in restrictions on the product or manufacturer, including withdrawal of
the product from the market. Further, governmental agencies may establish
additional regulations which could prevent or delay regulatory approval of our
products.
If we do not successfully complete clinical trials, we will not be able to
obtain FDA approval and sell our products.
To be able to market products in the United States, we must demonstrate,
through extensive preclinical studies and clinical trials, the safety and
efficacy of our processes and product candidates, together with the cells
produced by such processes in such products, for application in the treatment of
humans. We have completed pivotal clinical trials to demonstrate the safety and
biological activity of patient cells isolated and collected in the Isolex(R)
300i system. We plan to conduct additional trials to demonstrate safety and
efficacy for enhancements to the Isolex(R) 300i. If our clinical trials for
product enhancements to the Isolex(R) 300i, or if our other products are not
successful, our products may not be marketable.
Our ongoing studies may be delayed or halted for various reasons,
including:
. lack of effectiveness of our device is not effective, or the perception
by physicians that the device is not effective;
. failure of patients to enroll in the trials at the rate we expect;
. doubts among physicians and patients regarding the utility of stem cell
therapy; and
. side effects as a result of the treatment.
In addition, the FDA and foreign regulatory authorities have substantial
discretion in the approval process. The FDA and foreign regulatory authorities
may not agree that we have demonstrated that our products are safe and
effective.
4
<PAGE>
If the licenses we depend on are breached or terminated, we would lose our right
to develop and sell the products covered by the licenses.
We have obtained licenses to third-party technology to conduct parts of our
business, including technology supporting critical components of our Isolex(R)
system. We are the exclusive licensee in the field of therapeutic research to
patented technology from Becton Dickinson Company and Johns Hopkins University,
which technology relates to stem cell separation and particularly relates to the
separation of CD34 blood stem cells. If the licensors breach or terminate this
or other licenses, we may lose our rights to develop and market the products for
the purposes covered by the licenses, including the rights to develop and market
our Isolex(R) system. We may not be able to obtain additional licenses as may
be required for the development of our products on reasonable terms or at all.
If our patent and other intellectual property protection is inadequate, our
sales and profits could suffer or competitors could force our products out of
the market.
We own or license patents on which our products rely in four general patent
families:
. selection systems;
. bioreactor and culture systems;
. reagents for use in selection; and
. cell culture and cell compositions.
Four of our licensed patents relating to CD34 stem cell separation, a
critical application of the Isolex(R) system, currently are set to expire in
2004, 2007, 2110 and 2111, respectively. We may not be able to extend these or
any other patents. Competitors may develop products based upon the same
principles as our products, including the Isolex(R) system, and market those
products after our patents expire, or may design around our existing patents.
If this happens, our sales would suffer and profits could be severely impacted.
In addition, patents may be issued to others which prevent the manufacture or
sale of our products. We may have to license those patents and pay significant
fees or royalties to the owners of the patents in order to keep marketing our
products. This would cause profits on sales to suffer.
We have filed patent applications with respect to our potential products.
These patent applications and others which may be filed by us may not issue.
The scope of any patent that issues may not be sufficient to protect our
technology. The laws of foreign jurisdictions in which we sell and intend to
sell our products may not protect our rights to the same extent as the laws of
the United States.
In addition to patent protection, we also rely on trade secrets,
proprietary know-how and technology advances. We enter into confidentiality
agreements with our employees and others, but these agreements may not be
effective in protecting our proprietary information. Others may independently
develop substantially equivalent proprietary information or obtain access to our
know-how.
If we do not keep pace with technological and market changes, our products may
become obsolete and our business may suffer.
The market for our products is very competitive and is subject to rapid
technological changes. Our competitors may have developed, or could in the
future develop, new technologies
5
<PAGE>
that compete with our products or even render our products obsolete. Numerous
investigators are working in the fields for which our products are intended
for use. Given the unpredictable nature of medical research and clinical
development, studies have been and will continue to be published that are not
supportive of the uses of our products for which we intended. Even if we are
able to demonstrate improved or equivalent results of our products compared to
existing products, practitioners may not switch to our new products. Given the
experience and expertise associated with traditional cancer treatment methods,
if we cannot develop our cell selection procedure to lead to a less expensive
and quicker recovery time than seen with alternative treatment methods, we will
suffer a competitive disadvantage. Researchers are continually learning more
about cancer that may lead to new technologies to treat the disease. To the
extent that others develop new technologies that address cancer treatment, our
business will suffer.
The market for our products will depend on acceptance by physicians and
patients.
Market acceptance and demand for our products will depend largely on
acceptance by physicians and patients of the products as safe and effective
treatments and on the pricing of alternative products. Our technologies or
product candidates may not be accepted by the marketplace as readily as
competing or alternative processes or methodologies. Sales of our products have
generated growing but modest revenues to date. The Isolex(R) 300i cell selection
system has been approved for marketing in the United States. This is the only
one of our stem cell selection products that has received such approval. We
cannot assure that any of our products will gain any significant degree of
market acceptance in the United States or internationally among physicians,
hospital personnel, other health care providers and third-party payers, even if
reimbursement and necessary regulatory approvals are obtained. We believe that
the commercial success of our products will depend on such acceptance.
Acceptance will also depend upon our ability to train physicians, hospital
personnel and other health care providers to use the Isolex(R) system and our
other products, and the willingness of such individuals to learn to use these
products. Failure of our products to achieve significant market acceptance would
have a material adverse effect on our business, financial condition and results
of operations.
The success of sales of our products may depend upon reimbursements by third-
party payers.
In the United States, physicians, hospitals and other health care providers
that perform medical services generally rely on third-party payers, such as
government and private health insurance plans and health maintenance
organizations, to reimburse all or part of the cost associated with the
treatment of patients. Our ability to successfully commercialize our product
candidates will also depend on the extent to which these third party payers will
pay for the products and related treatments. Reimbursement by third party
payers depends on factors such as the payers' determination that use of the
products is safe and effective, medically necessary and not experimental or
investigational, appropriate for the patient and cost-effective. At present,
most third-party payers will reimburse for stem cell transplantation based on
fixed case rates. Many payers, however, still consider stem cell selection to
be experimental and investigational and have not included reimbursement for the
selection process in those case rates. A number of transplant centers in the
United States have in fact succeeded in negotiating higher case rates to include
reimbursement for the stem cell selection process, but there can be no assurance
that most or all of our customers will have such success in the United States or
foreign jurisdictions. Accordingly, reimbursement in the United States or
foreign jurisdictions may not be available or maintained for the Isolex(R)
system or any of our product candidates.
6
<PAGE>
If third party payers do not approve our products for reimbursement, sales
will suffer as transplant centers and patients opt for competing products or
alternative treatments. If we do not obtain approvals for adequate third-party
reimbursements, we may not be able to establish or maintain price levels
sufficient to realize an appropriate return on our investment in product
development. Any limits on reimbursement available from third-party payers may
reduce the demand for, or negatively affect the price of, our products.
We have limited experience with manufacturing and we depend on third parties,
who may not perform, manufacture, or distribute our products outside the United
States, Canada and Western Europe.
We have no in-house manufacturing capability and rely exclusively on Baxter
Healthcare Corporation for the manufacture of our Isolex(R) and MaxSep(R)
products, as well as the supplies associated with these products. We also
contract with Dynal Biotech, a Norwegian reagent company, for the supply of
paramagnetic beads for use in cell selection. We contract with other companies
for supply of monoclonal antibodies, reagents and/or plastics. We rely on
Baxter affiliates and other companies for the distribution and servicing of our
products outside of the United States, Canada and Western Europe. If third
parties do not successfully carry out their contractual duties or meet expected
deadlines, or if our supply of certain components or other materials is limited
or interrupted, we would not be able to conduct clinical trials or market our
product candidates on a timely and cost-competitive basis, if at all. Our
revenues may suffer as a consequence. We may not be able to maintain favorable
agreements with these parties and may not be able to locate acceptable
contractors, or enter into favorable agreements with them, to replace existing
contractors or to manufacture and distribute new products. If third party
agreements terminate at a critical time, we may not have manufacturing or
distribution capabilities to meet demand for our products.
To be successful, our products must be manufactured in compliance with
regulatory requirements and at acceptable costs. Manufacturing facilities of
the company's products are subject to GMP regulations, international quality
standards and other regulatory requirements. Failure by our contractors to
maintain their facilities in accordance with GMP regulations, international
quality standards or other regulatory requirements may entail a delay or
termination of production, which could have a material adverse effect on our
business, financial condition and results of operations.
Given our limited sales and marketing experience, we may not be able to develop
effective methods to sell and market our products.
Until late 1999, we relied on Baxter Healthcare Corporation for sales and
marketing of our products. We have established internal sales and marketing
capabilities and will be primarily responsible for sales and marketing of our
products. Our internal capabilities are inexperienced and may not be effective.
If we are not able to develop an effective sales and marketing organization, we
will have to arrange for such activities to be performed by contracted third
parties. We may not be able to enter into favorable agreements with such third
parties, if at all. Such failures could have a material adverse effect on our
business, financial condition and results of operations.
7
<PAGE>
Intellectual property litigation could harm our business.
Our success will depend in part on our ability to develop commercially
viable products without infringing the proprietary rights of others.
Litigation, which is very expensive, may be necessary to enforce or defend our
patents or proprietary rights and may not end favorably for us. Although we
have not been subject to any filed infringement claims based on third party
patents, other patents could exist or could be filed, which would prohibit or
limit our ability to market our products or maintain our competitive position.
On March 2, 2000, we filed suit against Miltenyi Biotec GmbH and their related
companies, Miltenyi Biotec, Inc. and AmCell Corporation. The suit charges
Miltenyi with patent infringement, breach of contract and deceptive trade
practices. Intellectual property litigation such as this could divert
management's attention from developing our products and could force us to incur
substantial costs regardless of whether we are successful. An adverse outcome
could subject us to increased competition in the United States. Any of our
patents, licenses or other intellectual property may be challenged, invalidated,
canceled, infringed or circumvented and may not provide any competitive
advantage to us.
Public attitudes towards cell therapy may negatively affect regulatory approval
or public perception of our products.
The commercial success of our product candidates will depend in part on
public acceptance of the use of cell therapy for the prevention or treatment of
human diseases. Public attitudes may be influenced by claims that cell therapy
is unsafe, and cell therapy may not gain the acceptance of the public or the
medical community. Adverse effects in the field of cell therapy that have
occurred or may occur in the future also may result in greater governmental
regulation of our product candidates and potential regulatory delays relating to
the testing or approval of our product candidates.
The ethical, legal and social implications of our research using stem cells
could prevent us from developing or gaining acceptance for commercially viable
products in this area.
Our research programs may involve the use of human stem cells that would be
derived from human tissue. The use of certain human stem cells gives rise to
ethical, legal and social issues regarding the appropriate use of these cells.
In the event that our research related to human stem cells becomes the subject
of adverse commentary or publicity, the market price for our common stock could
be significantly harmed.
We face certain risks associated with international sales of our products.
A number of risks are inherent in international operations and
transactions. International sales and operations may be limited or disrupted by
the imposition of government controls, export license requirements, political
instability, trade restrictions, changes in tariffs and difficulties in
staffing, coordinating and managing international operations. Additionally, our
business, financial condition and results of operations may be adversely
affected by fluctuations in international currency exchange rates as well as
constraints on our ability to maintain or increase prices. The international
nature of our business subjects us and our representatives, agents and
distributors to laws and regulations of the foreign jurisdictions in which they
operate or in which our products are sold. The regulation of medical devices in
a number of such jurisdictions, particularly in the European Union, continues to
develop. We cannot assure that new laws or
8
<PAGE>
regulations, or new interpretations of existing laws and regulations, will not
have a material adverse effect on our business, financial condition and results
of operations. In addition, the laws of certain foreign countries do not protect
our intellectual property rights to the same extent as do the laws of the United
States. We may not be able to successfully further commercialize our current
products or successfully commercialize any future products in any international
market.
We may not successfully compete in the biotechnology industry.
We compete with biotechnology companies, pharmaceutical companies, academic
institutions, government agencies and public and private research organizations.
Many of these entities have extensive resources and experience in research and
development, clinical testing, manufacturing, regulatory affairs, distribution
and marketing. Some of these entities have significant research and development
activities in areas upon which our programs focus. Many of our competitors
possess substantially greater research and development, financial, technical,
marketing and human resources than us and may be in a better position to
develop, manufacture and market products. We are aware of existing products
that compete with our products and other products in development that may
compete with our products. If we cannot successfully compete with existing or
new products, our marketing and sales will suffer and it may not ever be
profitable.
If we need additional financing and cannot obtain it, product development and
sales may be limited.
We may need to change our plans for development of our proposed products to
address difficulties with clinical studies or for sales of our existing products
to accommodate market demands. If that occurs, we may need to spend more funds
than currently anticipated. We may not be able to obtain additional funds on
commercially reasonable terms or at all. If adequate funds are not available,
we may be required to delay or terminate research and development programs,
curtail capital expenditures, reduce business development and other operating
activities or to obtain financing on terms not favorable to us.
If we do not attract and retain key management, consultants and scientific
personnel, our business may suffer.
We are highly dependent on our current management, consultants and
scientific personnel. Our success will largely depend upon our ability to
retain our current key personnel and consultants and to attract and retain new
highly qualified personnel. Expertise in the field of ex vivo cell research and
therapy is not generally available in the market, and competition for qualified
consultants, management and scientific personnel is intense. We may not be
successful in retaining existing or hiring new key consultants and personnel,
which may have an adverse effect on us.
9
<PAGE>
We may not have adequate insurance and may have substantial exposure to payment
of product liability claims.
We face an inherent business risk of exposure to product liability claims
in the event that the use of the Isolex(R) system during research and
development efforts, including clinical trials, or after commercialization
results in adverse effects. As a result, we may incur significant product
liability exposure, which could exceed existing product liability insurance
coverage. We may not be able to maintain our product liability insurance at an
acceptable cost, if at all. If claims or losses exceed our liability insurance
coverage, our financial condition would be adversely affected.
Our stock price and warrant price could be volatile and could decline.
The market prices for securities of biotechnology companies are highly
volatile, and there are significant price and volume fluctuations in the market
that may be unrelated to particular companies' operating performances. Our stock
price could decline suddenly due to factors such as the following:
. results of clinical trials;
. the amount of our cash resources and ability to obtain additional
funding;
. timing of regulatory approvals and changes in government regulation;
. fluctuations in operating results;
. announcements by us or others of technological innovations or new
products;
. failure to meet estimates or expectations of securities analysts;
. rate of product acceptance;
. developments in or disputes over patent or other proprietary rights;
. public concern as to the safety of products developed by us or by
others;
. changes in recommendations by securities analysts, if any; and
. general market conditions.
Any of these events may cause the price of our shares to fall, which may
adversely affect our business and financing opportunities. In addition, the
stock market in general and the market prices for biotechnology companies in
particular have experienced significant volatility that often has been unrelated
to the operating performance or financial conditions of such companies. These
broad market and industry fluctuations may adversely affect the trading price of
our shares, regardless of our operating performance or prospects. For example,
since December 31, 1999, the price of our common stock has fluctuated from a low
of $3.25 to a high of $25.75, and the price of our publicly traded warrants has
fluctuated from a low of $.6875 to a high of $5.50.
10
<PAGE>
Outstanding shares of convertible preferred stock and warrants could cause
substantial dilution.
As of September 30, 2000, our outstanding equity securities included:
. 74,498 shares of Series A Cumulative Convertible Preferred Stock,
convertible into 6,772,545 shares of common stock at a conversion price
of $11.00 per share;
. 63,000 shares of Series B Cumulative Convertible Preferred Stock,
convertible into 5,727272 shares of common stock at a conversion price
of $11.00 per share;
. Class B Warrants to purchase 750,000 shares of common stock for a price
of $12.00 per share; and
. warrants to purchase 1,300,000 shares of common stock for a price of
$4.60 per share.
. warrants to purchase 361,130 shares of common stock for a price of $5.40
per share.
If holders of the preferred stock and warrants listed above converted or
exercised all of their shares as of September 30, 2000, the holders would
receive approximately 14,911,000 shares of common stock (representing
approximately 39% of our outstanding shares on a fully diluted basis, including
approximately 2,212,000 shares of common stock upon the exercise of stock
options outstanding as of September 30, 2000). Investors in our common stock or
warrants could experience substantial dilution of their investment upon
conversion of the preferred stock or exercise of the warrants. Our outstanding
equity securities also include Class A Warrants to purchase up to 1,500,000
shares of common stock for a price of $.04 per share, which are not exercisable,
if at all, until November 24, 2004.
Future sales of shares may depress the price of our common stock.
If shareholders sell a substantial number of shares of our common stock in
the public market, or investors perceive that these sales might occur, the
market price of our common stock could decrease. Such a decrease could make it
difficult for us to raise capital by selling stock or to pay for acquisitions
using stock. To the extent outstanding options or warrants are exercised or
additional shares of capital stock are issued, investors purchasing our common
stock or securities convertible into common stock may incur additional dilution.
Our employees hold a significant number of options to purchase shares, many of
which are presently exercisable. Employees may exercise their options and sell
shares shortly after such options become exercisable, particularly if they need
to raise funds to pay for the exercise of such options or to satisfy tax
liabilities that they may incur in connection with exercising their options.
If shareholders do not receive dividends, shareholders must rely on stock
appreciation for any return on their investment.
We have never declared or paid cash dividends on any of our capital stock.
We currently intend to retain any earnings for future growth and, therefore, do
not anticipate paying cash dividends in the future. As a result, only
appreciation of the price of the warrants and/or common stock will provide a
return to investors who purchase or acquire securities pursuant to this
prospectus.
11
<PAGE>
Forward-Looking Statements
This prospectus contains forward-looking statements, including statements
regarding:
. plans and objectives of management for future operations, including
those relating to the development, sales and marketing of the Isolex(R)
products;
. statements preceded by, followed by, or including the words "believes,"
"expects," "intends," "estimates," "should," "may," or similar
expressions; and
. other statements contained or incorporated by reference in this
prospectus regarding matters that are not historical facts.
Because such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by such forward-
looking statements. Factors that could cause actual results to differ
materially include, but are not limited to:
. results of clinical trials;
. ability to enter into strategic collaborations with others;
. timing of product development;
. marketability of products;
. ability to obtain and protect patent and proprietary rights;
. competition and technological change;
. extent of developing sales and marketing capabilities;
. ability to obtain third-party reimbursement;
. existence of hazardous materials;
. potential product liability and availability of insurance;
. future capital needs and ability to obtain additional funding; and
. timing and receipt of regulatory approval.
Although we believe that the expectations reflected in the forward-looking
statements as of this date are reasonable, we cannot assure that the
expectations will prove to have been correct. All phases of our operations are
subject to uncertainties, risks and other influences, many of which are outside
our control. Any one, or a combination, of those uncertainties, risks or other
influences could materially adversely affect our results of operations, whether
or not the forward-looking statements ultimately prove to be accurate.
12
<PAGE>
We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise.
You are advised, however, to consult any additional disclosures we make in our
Form 10-Q, 8-K and 10-K reports to the SEC.
13
<PAGE>
Use Of Proceeds
We cannot guarantee that we will receive any proceeds in connection with
this offering.
We intend to use the net proceeds of this offering, if any, to fund
research, development and product manufacturing, to provide working capital and
for general corporate purposes. We may also use a portion of the net proceeds
to acquire or invest in businesses, products and technologies that are
complementary to our own. Pending these uses, the net proceeds will be invested
in investment-grade, interest-bearing securities.
The principal proposes of this offering are to increase our capitalization
and our operating and financial flexibility. As of the date of this prospectus,
we cannot specify with certainty all of the particular uses for the net proceeds
we will have upon completion of this offering. Accordingly, our management will
have broad discretion in the application of net proceeds, if any.
Based upon our current operating plan, we believe that our available cash
and existing sources of revenue, together with the proceeds of this offering, if
any, and interest earned thereon, will be adequate to satisfy our capital needs
until at least the end of the year 2001.
14
<PAGE>
Plan of Distribution
General
We may sell securities to one or more underwriters for public offering
and sale by them and may also sell securities to investors directly or through
agents. We have reserved the right to sell securities directly to investors on
our own behalf in those jurisdictions where and in such manner as we are
authorized to do so.
The distribution of the securities may be effected from time to time
in one or more transactions at a fixed price or prices, which may be changed, or
at market prices prevailing at the time of sale, at prices related to such
prevailing market prices, or at negotiated prices. Sales of common stock
offered pursuant to this registration statement may be effected from time to
time in one or more transactions on the Nasdaq National Market or in negotiated
transactions or a combination of these methods. We may also, from time to time,
authorize dealers, acting as our agents, to offer and sell securities upon the
terms and conditions as are set forth in the applicable prospectus supplement.
In connection with the sale of securities, underwriters may receive compensation
from us in the form of underwriting discounts or commissions and may also
receive commissions from purchasers of the securities for whom they may act as
agent.
Underwriters may sell securities to or through dealers, and the
dealers may receive compensation in the form of discounts, concessions or
commissions from the underwriters and/or commissions from the purchasers for
whom they may act as agent. Dealers and agents participating in the
distribution of securities will be deemed to be underwriters, and any discounts
and commissions received by them and any profit realized by them on resale of
the securities will be deemed to be underwriting discounts and commissions.
Unless otherwise indicated in a prospectus supplement, an agent will be acting
on a best efforts basis and a dealer will purchase securities as a principal,
and may then resell the securities at varying prices to be determined by the
dealer.
Any underwriter, dealer or agent involved in the offer and sale of
securities will be identified, and any compensation paid by us to underwriters
or agents in connection with the offering of securities, and any discounts,
concessions or commissions allowed by underwriters to participating dealers,
will be set forth in the applicable prospectus supplement.
Underwriters, dealers and agents may be entitled, under agreements
entered into with us, to indemnification against and contribution toward certain
civil liabilities, including liabilities under the Securities Exchange Act, and
to reimbursement by us for certain expenses.
To facilitate an offering of a series of securities, certain persons
participating in the offering may engage in transactions that stabilize,
maintain, or otherwise affect the price of the securities. This may include
over-allotments or short sales of the securities, which involves the sale by
persons participating in the offering of more securities than have been sold to
them by us. In such circumstances, such persons would cover the over-allotments
or short positions by purchasing in the open market or by exercising the over-
allotment option granted to such persons. In addition, such persons may
stabilize or maintain the price of the securities by bidding for or purchasing
securities in the open market or by imposing penalty bids, whereby selling
concessions allowed to dealers participating in any such offering may be
reclaimed if securities sold by them are repurchased in connection with
stabilization transactions. The effect of these transactions may be to
stabilize or maintain the market price of the securities at a level above that
which might otherwise prevail in the open market. Such transactions, if
commenced, may be discontinued at any time.
Equity Line of Credit
We have entered into a common stock purchase agreement with Acqua
Wellington North American Equities Fund, Ltd. pursuant to which we may, from
time to time and at our sole discretion, beginning in January 2001 and ending
November 2002, present Acqua Wellington with draw down notices constituting an
offer to purchase our common stock over an agreed to number of consecutive
trading days. Acqua Wellington will be required to purchase a pro rata portion
of shares on each day during the trading day period on which the daily weighted
average price of our common stock exceeds a threshold price determined by us and
set forth in the draw down notice. In addition, we may, at our sole discretion,
grant Acqua Wellington an option to purchase additional shares during such
trading period. The aggregate amount Acqua Wellington will be required to
invest during any draw down period will depend on the threshold price
established by us for the draw down period.
The aggregate amount invested by Acqua Wellington pursuant to the
common stock purchase agreement will not exceed $23 million. We will issue and
sell the shares to Acqua Wellington at a price per share equal to the daily
volume weighted average price of our common stock on each date during the draw
down period on which shares are purchased, less a discount ranging from 7.0% to
11.0%. We may present Acqua Wellington with up to 18 draw notices during the
term of the common stock purchase agreement, provided there are at least five
trading days between each draw down period.
Acqua Wellington may be deemed to be an underwriter within the meaning
of Section 2(a)(11) of the Securities Act of 1933, as amended. The purchase
price discount to our then-current market price would accordingly be deemed to
be underwriting discounts and commissions.
Our common stock may be sold from time to time by Acqua Wellington, by
a broker-dealer or by pledgees, donees, transferees or other successors in
interest. Such sales may be made on the Nasdaq National Market at prices and at
terms then prevailing or at prices related to the then current market price, or
in negotiated private transactions, or in a combination of these methods. Acqua
Wellington under the common stock purchase agreement will pay all commissions
and certain other expenses associated with the sale of the common stock it
acquired pursuant to the equity line of credit arrangement. In effecting sales,
any broker-dealer engaged by Acqua Wellington may arrange for other broker-
dealers to participate. The common stock may be sold in one or more of the
following manners:
. a block trade in which the broker or dealer so engaged will attempt
to sell the shares as agent, but may position and resell a portion of the block
as principal to facilitate the transaction;
. purchases by a broker-dealer for its account under this prospectus;
. short sales;
. through the writing of options on the shares;
. ordinary brokerage transactions and transactions in which the
broker solicits purchasers; or
. a combination of any such methods of sale.
Such broker-dealers and any other participating broker-dealers may be deemed to
be underwriters in connection with such sales.
Except as disclosed in a supplement to this prospectus, no broker-
dealer will be paid more than a customary brokerage commission in connection
with any sale of the common stock acquired by the purchaser pursuant to the
equity line of credit arrangement. Broker-dealers may receive commissions,
discounts or other concessions from Acqua Wellington in amounts to be negotiated
immediately prior to the sale. The compensation to a particular broker-dealer
may be in excess of customary commissions. Profits on any resale of the common
stock as a principal by such broker-dealer and any commissions received by such
broker-dealer may be deemed to be underwriting discounts and commissions under
the Securities Act.
Under the terms of the common stock purchase agreement, Acqua
Wellington would be able to enter into hedging transactions with broker-dealers
and the broker-dealers may engage in short sales of the common stock in the
course of hedging the positions they assume with Acqua Wellington, including,
without limitation, in connection with distributions of the common stock by such
broker-dealers. Acqua Wellington may enter into option or other transactions
with broker-dealers that involve the delivery of the shares offered pursuant to
this registration statement to the broker-dealers, who may then resell or
otherwise transfer the shares. In addition, Acqua Wellington may also loan or
pledge the shares offered pursuant to this registration statement to a broker-
dealer and the broker-dealer may sell the shares so loaned or upon a default may
sell or otherwise transfer the pledged shares offered pursuant to this
registration statement.
Acqua Wellington and any other persons participating in the sale or
distribution of the shares covered by this prospectus or any prospectus
supplement will be subject to liability under the federal securities laws and
must comply with the requirements of the Securities Act and the Securities
Exchange Act, including without limitation, Rule 10b-5 and Regulation M. These
rules and regulations may limit the timing of purchases and sales of any of the
shares by the purchaser or any other person. Under these rules and regulations,
Acqua Wellington and any other persons participating in the sale of
distribution:
. may not engage in any stabilization activity in connection with our
securities;
. must furnish each broker which offers shares of our common stock
covered by this prospectus with the number of copies of this prospectus and any
prospectus supplement which are required by each broker; and
. may not bid for or purchase any of our securities or attempt to
induce any person to purchase any of our securities other than as permitted
under the Securities Exchange Act.
These restrictions may affect the marketability of the shares.
Under the terms of the common stock purchase agreement, Acqua
Wellington may have the right to engage in short sales of the common stock to be
acquired by it pursuant to the common stock purchase agreement, provided that
Acqua Wellington does not sell more shares of common stock than Acqua Wellington
purchases. Acqua Wellington has covenanted in the common stock purchase
agreement that, prior to and during the twenty-two consecutive months following
the effective date of the common stock purchase agreement, it and its affiliates
will not sell any shares of our common stock acquired by them pursuant to the
common stock purchase agreement, including by:
. any swap
. any short sale;
. any hedge; or
. any other such agreement which transfers the economic risk of
ownership of our common stock;
except with respect to shares of our common stock that they acquired pursuant to
the common stock purchase agreement. Any short sales by the purchaser would
comply with the requirements of the Securities Act and the Securities Exchange
Act, including without limitation, Regulation M.
In connection with Acqua Wellington's purchase and potential resale of
the shares covered by this registration statement, we have agreed to indemnify
and hold harmless Acqua Wellington and, possibly, any broker-dealers and agents
who Acqua Wellington sells through and who may be deemed to be underwriters with
respect to securities covered by this registration statement, against certain
liabilities, including liabilities under the Securities Act, which may be based
upon, among other things, any untrue statement or alleged untrue statement of a
material fact or any omission or alleged omission of a material fact, unless
made or omitted in reliance upon written information provided to us by Acqua
Wellington. We have also agreed to reimburse Acqua Wellington for certain
expenses it incurs in connection with the negotiation and execution of the
common stock purchase agreement, the filing of any prospectus supplements and
for certain due diligence costs in connection with draw-downs on the equity line
of credit.
DILUTION
The common stock purchase agreement that we have entered into with
Acqua Wellington provides that Acqua Wellington may purchase shares of our
common stock at a discount of up to 11.0%, to be determined based on our market
capitalization at the start of the draw-down period. As a result, our existing
common stockholders will experience immediate dilution upon the purchase of any
shares of our common stock by Acqua Wellington.
Net tangible book value per share represents the amount of our
tangible assets less total liabilities, divided by 19,084,894 shares of common
stock. At September 30, 2000, our net tangible book value was $29,287,000
million, or approximately $1.53 per share of common stock. Should Acqua
Wellington purchase the full $23,000,000 of common stock remaining under this
registration statement at a 11% discount, assuming a market value of $3.00 per
share, Acqua Wellington would acquire 8,614,232 shares of common stock with a
total market value of $25,843,000. As a result, our net tangible book value
would increase by $0.36 per share from our net book value at September 30, 2000
and $0.42 per share from our tangible net book value had Acqua Wellington
purchased the common stock without the 11% discount. The common stock purchase
agreement with Acqua Wellington provides that Acqua Wellington will purchase a
certain dollar amount of shares, with the exact number of shares to be
determined based on the per share market price of our common stock on a
particular trading day. As a result, if the per share market price of our common
stock declines, Acqua Wellington will receive a greater number of shares for its
purchase price, thereby resulting in further dilution to our stockholders.
15
<PAGE>
Where You Can Find More Information
We file annual, quarterly and special reports, proxy statements and other
information with the SEC. You may read and copy any document we file at the
SEC's public reference room at 450 Fifth Street, N.W., Washington, D.C., 20549.
You can request copies of these documents by contacting the SEC and paying a fee
for the copying cost. Please call the SEC at 1-800-SEC-0330 for further
information on the public reference rooms. Our SEC filings are also available to
the public from the SEC's website at www.sec.gov.
This prospectus is part of a registration statement on Form S-3, including
amendments, relating to the common stock offered by this prospectus with the
SEC. This prospectus does not contain all of the information set forth in the
registration statement, the exhibits and schedules, some portions of which the
SEC allows us to omit. Statements contained in this prospectus as to the
contents of any contract or other document referred to are not necessarily
complete and in each instance reference is made to the copy of that contract or
other document filed as an exhibit to the registration statement. For further
information about us and the common stock offered by this prospectus we refer
you to the registration statement and its exhibits and schedules which may be
obtained as described above.
The SEC allows us to "incorporate by reference" the information contained
in documents that we file with them, which means that we can disclose important
information to you by referring you to those documents. The information
incorporated by reference is considered to be part of this prospectus.
Information in this prospectus supersedes information incorporated by reference
that we filed with the SEC before the date of this prospectus, while information
that we file later with the SEC will automatically update and supersede prior
information. We incorporate by reference the documents listed below and any
future filings we will make with the SEC under Sections 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934, as amended, prior to the
termination of the offering:
1. our Annual Report on Form 10-K for the fiscal year ended December 31,
1999;
2. our Quarterly Reports on Form 10-Q for the quarters ended March 31,
2000, June 30, 2000 and September 30, 2000;
3. our Current Reports on Form 8-K, filed July 19, 2000 and June 22, 2000;
and
4. the description of our common stock contained in our registration
statement on Form S-3 filed May 10, 1999.
You may request copies of these filings, at no cost, by writing or
telephoning us at:
Nexell Therapeutics Inc.
9 Parker
Irvine, California 92618
Attention: Corporate Communications
Telephone (949) 470-9011
16
<PAGE>
Legal Matters
The validity of the issuance of the common stock offered in this prospectus
will be passed upon for Nexell Therapeutics Inc. by Latham & Watkins, Menlo
Park, California. Latham & Watkins does not beneficially own any shares of
common stock as of the date of this prospectus.
Experts
The consolidated financial statements of Nexell Therapeutics Inc. as of
December 31, 1999 and 1998, and for each of the years in the three-year period
ended December 31, 1999, have been incorporated herein by reference and in the
registration statement in reliance upon the report of KPMG LLP, independent
auditors, incorporated by reference herein, and upon the authority of said firm
as experts in accounting and auditing.
17
<PAGE>
PART II
Information Not Required In Prospectus
Item 14. Other expenses of issuance and distribution.
The estimated expenses payable by Nexell in connection with this offering
are as follows:
<TABLE>
<CAPTION>
<S> <C>
Registration Fees.......................... $ 6,600
Legal Fees................................. $ 75,000
Accounting Fees............................ $ 8,000
Printing Expenses.......................... $ 5,000
Miscellaneous.............................. $ 6,000
Total...................................... $100,600
</TABLE>
Item 15. Indemnification of directors and officers.
Pursuant to Section 102 of the Delaware General Corporation Law (the
"DGCL"), the Registrant's Certificate of Incorporation contains the following
provision regarding limitation of liability of directors and officers:
A director of this corporation shall not be personally liable to the
corporation or its stockholders for monetary damages for the breach of any
fiduciary duty as a director, except in the case of (a) any breach of the
director's duty of loyalty to the corporation or its stockholders, (b) acts
or omissions not in good faith or that involve intentional misconduct or a
knowing violation of law, (c) under section 174 of the General Corporation
Law of the State of Delaware or (d) for any transaction from which the
director derives an improper personal benefit. Any repeal or modification
of this Article by the stockholders of the corporation shall not adversely
affect any right or protection of a director of the corporation existing at
the time of such repeal or modification with respect to acts or omissions
occurring prior to such repeal or modification.
The Registrant is empowered by Section 145 of the DGCL, subject to the
procedures and limitation stated therein, to indemnify any person against
expenses (including attorney's fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred by him in connection with any
threatened, pending or completed action, suit or proceeding in which such person
is made a party by reason of his being or having been a director, officer,
employer or agent of the Registrant. The statute provides that indemnification
pursuant to its provisions is not exclusive of other rights of indemnification
to which a person may be entitled under any by-law, agreement, vote of
stockholders or disinterested directors, or otherwise. The Registrant's
Certificate of Incorporation and the Registrant's By-laws both provide for
indemnification of its officers and directors to the full extent permitted by
the DGCL, including circumstances in which indemnification is otherwise
discretionary.
Item 16. Exhibits
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<C> <S>
2.4 Asset Purchase Agreement dated October 10, 1997 by and among
</TABLE>
II-1
<PAGE>
<TABLE>
<C> <S>
Baxter Healthcare Corporation ("Baxter"), the Company and NCI. (1)
2.5 Asset Acquisition Agreement dated February 18, 1999, by and among
Baxter, the Company and NCI. (2)
2.6 Securities Agreement dated as of November 24, 1999 among the
Company and the Purchasers named in Schedule I thereto (certain
schedules are omitted and the Company agrees to furnish
supplementally a copy to the Commission upon request. (3)
4.4 Warrant Agreement dated June 17, 1996 between the Company and
American Stock Transfer & Trust Company. (4)
4.5 The Certificate of Amendment of the Certificate of Incorporation
of the Company filed with the Delaware Secretary of State on
December 16, 1997 creating a Series A Preferred Stock and
amendments subsequent thereto. (3)
4.6 The Certificate of Amendment of the Certificate of Incorporation
of the Company filed with the Delaware Secretary of State on May
25, 1999 modifying the Series A Preferred Stock. (3)
4.7 The Company's Series 1 6 1/2 % Convertible Subordinated Debenture
Due November 30, 2004 issued May 28, 1999 to Baxter. (5)
4.8 The Company's Series 2 6 1/2 % Convertible Subordinated Debenture
Due November 30, 2004 issued May 28, 1999 to Baxer. (5)
4.9 The Company's Certificate of Designation filed with the Delaware
Secretary of State on November 24, 1999 creating the Series B
Preferred Stock. (3)
4.10 Registration Rights Agreement dated as of November 24, 1999 among
the Company and the Investors identified therein. (3)
5.1 Opinion of Latham & Watkins. (6)
10.1* Common Stock Purchase Agreement dated as of January 9, 2001, by
and between Nexell Therapeutics Inc. and Acqua Wellington North
American Equities Fund, Ltd.
23.1* Consent of KPMG LLP.
23.2 Consent of Latham & Watkins. (6)
24.1 Power of attorney. (6)
</TABLE>
_____________
* Filed herewith.
(1) Filed as the same numbered Exhibit to the Company's Current Report on
Form 8-K filed January 2, 1998 and incorporated herein by reference.
(2) Filed as the same numbered Exhibit to the Company's Annual Report on
Form 10-K for the year ended December 31, 1998 and incorporated herein by
reference.
(3) Filed as the same numbered Exhibit to the Company's Current Report on
Form 8-K filed December 7, 1999 and incorporated herein by reference.
(4) Filed as the same numbered Exhibit to the Company's Annual Report on
Form 10-K for the year ended December 31, 1996 and incorporated herein by
reference.
II-2
<PAGE>
(5) Filed as the same numbered Exhibit to the Company's Current Report on
Form 8-K filed June 29, 1999 and incorporated herein by reference.
(6) Previously filed.
Item 17. Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent post-
effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or
decrease in the volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the "Calculation of Registration Fee" table in
the effective registration statement.
(iii) To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any
material change to such information in the registration statements.
(2) That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the termination of the
offering.
(4) Insofar as indemnification for liabilities arising under the Securities
Act of 1933, as amended (the "Act"), may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or
otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission, such indemnification is against public policy as
expressed in the act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director,
officer, or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by the final adjudication of
such issue.
II-3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
certifies that it has reasonable grounds to believe that it meets all the
requirements for filing on Form S-3, and has duly caused this Post Effective
Amendment No. 1 to the Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Irvine, State of
California on January 8, 2001.
NEXELL THERAPEUTICS INC.
By: /s/ William A. Albright, Jr.
----------------------------
William A. Albright, Jr.
President and Chief Operating Officer
Pursuant to the requirements of the Securities Act of 1933, this Post
Effective Amendment No. 1 to the Registration Statement has been signed below by
the following persons in the capacities indicated on January 8, 2001.
<TABLE>
<CAPTION>
Signatures Title
---------- -----
<S> <C>
* Chairman and Chief Executive
---------------------------------- Officer
Richard L. Dunning
/s/ William A. Albright, Jr. President, Chief Operating
---------------------------------- Officer, Chief Financial Officer,
William A. Albright, Jr. and Principal Accounting Officer
* Director
----------------------------------
C. Richard Piazza
* Director
----------------------------------
</TABLE>
II-4
<PAGE>
<TABLE>
<S> <C> <C>
Joseph A. Mollica, Ph.D.
* Director
----------------------------------
Richard L. Casey
* Director
----------------------------------
Eric A. Rose, M.D.
* Director
----------------------------------
Daniel Levitt, Ph.D., M.D.
* Director
----------------------------------
Victor W. Schmitt
</TABLE>
By: /s/ William A. Albright
---------------------------
William A. Albright
Attorney-in-Fact
II-5
<PAGE>
Exhibit Index
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<C> <S>
2.4 Asset Purchase Agreement dated October 10, 1997 by and among
Baxter Healthcare Corporation ("Baxter"), the Company and NCI. (1)
2.5 Asset Acquisition Agreement dated February 18, 1999, by and among
Baxter, the Company and NCI. (2)
2.6 Securities Agreement dated as of November 24, 1999 among the
Company and the Purchasers named in Schedule I thereto (certain
schedules are omitted and the Company agrees to furnish
supplementally a copy to the Commission upon request. (3)
4.4 Warrant Agreement dated June 17, 1996 between the Company and
American Stock Transfer & Trust Company (4)
4.5 The Certificate of Amendment of the Certificate of Incorporation
of the Company filed with the Delaware Secretary of State on
December 16, 1997 creating a Series A Preferred Stock and
amendments subsequent thereto. (3)
4.6 The Certificate of Amendment of the Certificate of Incorporation
of the Company filed with the Delaware Secretary of State on May
25, 1999 modifying the Series A Preferred Stock. (3)
4.7 The Company's Series 1 6 1/2 % Convertible Subordinated Debenture
Due November 30, 2004 issued May 28, 1999 to Baxter. (5)
4.8 The Company's Series 2 6 1/2 % Convertible Subordinated Debenture
Due November 30, 2004 issued May 28, 1999 to Baxer. (5)
4.9 The Company's Certificate of Designation filed with the Delaware
Secretary of State on November 24, 1999 creating the Series B
Preferred Stock. (3)
4.10 Registration Rights Agreement dated as of November 24, 1999 among
the Company and the Investors identified therein. (3)
5.1 Opinion of Latham & Watkins. (6)
10.1* Common Stock Purchase Agreement dated as of January 9, 2001, by
and between Nexell Therapeutics Inc. and Acqua Wellington North
American Equities Fund, Ltd.
23.1* Consent of KPMG LLP.
23.2 Consent of Latham & Watkins. (6)
24.1 Power of attorney. (6)
</TABLE>
_____________
* Filed herewith.
(1) Filed as the same numbered Exhibit to the Company's Current Report on
Form 8-K filed January 2, 1998 and incorporated herein by reference.
(2) Filed as the same numbered Exhibit to the Company's Annual Report on
Form 10-K for the year ended December 31, 1998 and incorporated herein by
reference.
<PAGE>
(3) Filed as the same numbered Exhibit to the Company's Current Report on
Form 8-K filed December 7, 1999 and incorporated herein by reference.
(4) Filed as the same numbered Exhibit to the Company's Annual Report on
Form 10-K for the year ended December 31, 1996 and incorporated herein by
reference.
(5) Filed as the same numbered Exhibit to the Company's Current Report on
Form 8-K filed June 29, 1999 and incorporated herein by reference.
(6) Previously filed.
